High dose recombinant human erythropoietin use is associated with increased overall survival in patients with multiple myeloma.

被引：0
|
作者：
Baz, R
Brand, C
McGowan, B
Yiannaki, E
Hussein, MA
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[2] Cleveland Clin Myeloma Program, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：590S / 590S
页数：1
相关论文
共 50 条
  • [1] Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma
    Baz, R.
    Walker, E.
    Choueiri, T. K.
    Abou Jawde, R.
    Brand, C.
    McGowan, B.
    Yiannaki, E.
    Andresen, S.
    Hussein, M. A.
    ACTA HAEMATOLOGICA, 2007, 117 (03) : 162 - 167
  • [2] RECOMBINANT HUMAN ERYTHROPOIETIN IS ASSOCIATED WITH REDUCED OVERALL SURVIVAL IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE IN 312 PATIENTS
    Katodritou, E.
    Verrou, E.
    Hadjiaggelidou, C.
    Gastari, V.
    Spyrou, A.
    Konstantinidou, P.
    Lazaridou, A.
    Konstantinou, N.
    Zervas, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 437 - 437
  • [3] Recombinant human erythropoietin and overall survival
    Charles L. Loprinzi
    Current Oncology Reports, 2005, 7 (4) : 269 - 270
  • [4] Body mass index and overall survival in multiple myeloma.
    Wang, Bei
    Derman, Benjamin Avi
    Langerman, Spencer
    Stepniak, Elizabeth
    Johnson, Julie
    Zhang, Wei
    Jakubowiak, Andrzej J.
    Chiu, Brian C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Recombinant human erythropoietin for the treatment of anemia in patients with multiple myeloma
    Bourantas, K
    Tsiara, S
    Konstantinidou, P
    MitsulisMentsikoff, V
    Christou, L
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1996, 15 (04) : 371 - 374
  • [6] Recombinant human erythropoietin for the treatment of anemia in patients with multiple myeloma
    Bourantas, KL
    Tsiara, S
    Kapsali, E
    Christou, L
    Kaiafas, P
    ANNALS OF ONCOLOGY, 1998, 9 : 82 - 83
  • [7] High expression of MUM1/IRF4 mRNA is associated with a shorter overall survival in patients with multiple myeloma.
    Heintel, D
    Zojer, N
    Strasser-Weippl, K
    Vesely, M
    Gisslinger, H
    Drach, J
    Gaiger, A
    Jäger, U
    Ludwig, H
    BLOOD, 2005, 106 (11) : 445A - 445A
  • [8] Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia
    Mittelman, M
    Zeidman, A
    Fradin, Z
    Magazanik, A
    Lewinski, UH
    Cohen, A
    ACTA HAEMATOLOGICA, 1997, 98 (04) : 204 - 210
  • [9] THE FREQUENCY OF CYTOGENETIC ABNORMALITIES AND THEIR IMPACT ON OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.
    Garifullin, A.
    Voloshin, S.
    Martynkevich, I.
    Bessmeltsev, S.
    Martynenko, L.
    Kleina, E.
    Salogub, G.
    Karyagina, E.
    Schmidt, A.
    Kuvshinov, A.
    Abdulkadyrov, K.
    HAEMATOLOGICA, 2015, 100 : 733 - 733
  • [10] STUDY OF EFFICACY RECOMBINANT HUMAN ERYTHROPOIETIN IN MULTIPLE MYELOMA PATIENTS WITH ANEMIA
    Romanenko, N.
    Golovtshenko, R.
    Kostroma, I.
    Abdulkadyrov, K.
    HAEMATOLOGICA, 2012, 97 : 622 - 622
12345